Clinical trials: Inflammatory Breast Carcinoma
Breast Cancer, Cancer Survivor
Hypnosis in Treating Hot Flashes in Breast Cancer Survivors
RATIONALE: Hypnosis may be effective in decreasing hot flashes in breast cancer survivors. PURPOSE: This randomized clinical trial is studying how well hypnosis works in treating hot flashes in breast cancer survivors.
- Conditions
- Breast Cancer, Cancer Survivor, Hot Flashes
- Trial name
- NCT00094133
- Testing
- hot flashes attenuation, hypnotherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Scott and White Hospital & Clinic
Breast Cancer
Chemotherapy Induced Cognitive Impairment
Chemotherapy is toxic and challenges everyone differently. Most chemotherapy side-effects are known and well documented. However, the phenomenon of "chemo fog" also known as "chemobrain" has not been fully investigated and is…
- Trial name
- CONCERT (NCT05740787)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Aberdeen
Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
This phase I/II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination chemotherapy in treating patients with breast…
- Conditions
- Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7
- Trial name
- NCT03101748
- Testing
- Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Early Breast Cancer, Locally Advanced Breast Cancer
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use (PH FDC SC) administration in the home…
- Conditions
- Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
- Trial name
- ProHer (NCT05415215)
- Testing
- Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Where
- 45 sites in Argentina, Bosnia and Herzegovina and 15 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer
This study examines the relationship among epigenetic alterations and the development and persistence of psychoneurologic symptoms (cognitive dysfunction, depressive symptoms, anxiety, fatigue, sleep disturbance, and pain) in…
- Trial name
- NCT01411943
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Virginia Commonwealth University
Metastatic Breast Cancer, Breast Cancer
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer.
- Trial name
- NCT05243641
- Testing
- Neratinib, Capmatinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Nausea
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea.
- Trial name
- NCT00475085
- Testing
- aprepitant, dexamethasone, granisetron hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 1,021 people
- Sponsor
- Joseph Roscoe
Breast Cancer
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NRR (NCT00006110)
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cancer, Breast
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced /Inflammatory HER2-positive Breast Cancer…
- Trial name
- IMMUN-HER (NCT03144947)
- Testing
- Trastuzumab IV, Trastuzumab SC, Pertuzumab
- Where
- 21 sites in Italy
- Volunteers
- 65 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Neoplasms, Breast
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
This study was designed to determine how effective and safe a new investigational drug, lapatinib, is in treating patients with treatment refractory or relapsed inflammatory breast cancer.
- Trial name
- NCT00105950
- Testing
- lapatinib
- Where
- 27 sites in United States, Belgium and 6 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Biomarkers in Native American Women With Breast Cancer
RATIONALE: Studying samples of tumor tissue in the laboratory from Native American women with breast cancer may help doctors identify and learn more about biomarkers related to breast cancer in these patients.
- Trial name
- NCT00898976
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 120 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Erector Spinae Plane Block, Systemic Immune-inflammatory Index
Investigation of the Effect of Erector Spinae Plane Block on Systemic Immuno-Inflammatory Index
Erector spinae plane block (ESPB) is a novel interfascial block technique first described by Forero in 2016. It has been reported to be effective in various clinical indications.
- Conditions
- Erector Spinae Plane Block, Systemic Immune-inflammatory Index, Breast Cancer
- Trial name
- NCT06954324
- Testing
- Erector spinae plane block
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Namik Kemal University
Breast Cancer
Feasibility and Effectiveness of Sentinel Lymph Node Biopsy in Inflammatory Breast Cancer
This study is for participants with inflammatory breast cancer (IBC). The purpose of this study is to find out whether it is possible to take a sample of underarm lymph nodes for participants with IBC.
- Trial name
- NCT07876986
- Testing
- Sentinel node biopsy with blue dye and radioisotope
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms
FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.
FATLAS is a prospective, interventional, non Investigational Medicinal Product (IMP) study aiming to characterize the micro- and macroenvironment of breast cancer according to patient adiposity in different histological and…
- Trial name
- FATLAS (NCT04200768)
- Testing
- Prospective data and sample collection
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cardiovascular Diseases
Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study
The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary…
- Trial name
- HER-CROWN (NCT05632601)
- Testing
- PET scan
- Where
- Canada
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation
Breast Cancer
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
The goal of this clinical research study is to learn if Ofev® (nintedanib, also called BIBF1120) can help to control IBC. The safety of this drug will also be studied. This is an investigational study.
- Trial name
- NCT02389764
- Testing
- BIBF 1120, Phone Call
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer
- Trial name
- NCT00003199
- Testing
- tamoxifen citrate, busulfan, thiotepa
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Inflammatory Breast Cancer
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer.
- Trial name
- PELICAN (NCT03515798)
- Testing
- Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy
- Where
- 12 sites in France
- Volunteers
- 52 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer Female, Depressive Symptoms
The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients
The purpose of this study is to examine two mechanistic changes: emotion processing (awareness, expression and acceptance) and cholinergic anti-inflammatory processes (HRV and cytokine expression) through which an Art Therapy…
- Conditions
- Breast Cancer Female, Depressive Symptoms, Fatigue, Pain
- Trial name
- REPAT (NCT03377816)
- Testing
- Art Therapy
- Where
- Israel
- Volunteers
- 318 people
- Sponsor
- University of Haifa